Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced that Harry F. Hixson, Jr., Ph.D., will retire as Chief Executive Officer (CEO), effective as of the Company’s 2014 Annual Meeting on June 10, 2014. William J. Welch, the Company’s current President and Chief Operating Officer, will assume the role of CEO, effective as of the Annual Meeting and immediately upon Dr. Hixson’s retirement as CEO. Sequenom, Inc. (NASDAQ:SQNM) shares after opening at $2.32 on last trade day and at the end of the day closed at $2.48. Company price to sales ratio in past twelve months was calculated as 1.77 and price to cash ratio as 4.03. Sequenom, Inc. (NASDAQ:SQNM) showed a negative weekly performance of 6.44%.
TheStreet Quant Ratings rates OXiGENE Inc (NASDAQ:OXGN) as a sell. The company’s weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and disappointing return on equity. OXiGENE Inc (NASDAQ:OXGN) shares fell -7.73% in last trading session and ended the day on $198.80. OXGN return on equity ratio is recorded as -212.60% and its return on assets is 180.80%. OXiGENE Inc (NASDAQ:OXGN)yearly performance is -8.19%.
BG Medicine, Inc. (NASDAQ:BGMD) announced that the company will host a conference call and webcast on Thursday, March 20, 2014 at 8:30 a.m. Eastern Time to discuss its fiscal year 2013 financial results before the market opens. BG Medicine, Inc. (NASDAQ:BGMD) shares moved down -8.65% in last trading session and was closed at $1.69, while trading in range of $1.57 – $1.79. BG Medicine, Inc. (NASDAQ:BGMD) year to date (YTD) performance is 62.50%.
Inovio Pharmaceuticals (NYSE:INO) had its price target upped by Maxim Group from $3.00 to $6.00 in a research note issued to investors on Tuesday, Analyst Ratings.Net reports. The firm currently has a buy rating on the stock.Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is 8.83%. On last trading day company shares ended up $3.82. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is 31.25%. Analysts mean target price for the company is $3.80.
Leave a Reply